Table 3 Pathologic outcomes of patients classified according to the prostate weight
Prostate weight measured by TRUS (g) | < 25 g | 25–50 g | 51–75 g | > 75 g | P-value |
|---|---|---|---|---|---|
Patients (n) | 157 | 824 | 149 | 38 | |
Extracapsular extension | 0.003 | ||||
Negative | 87 (55.4%) | 430 (52.2%) | 104 (69.8%) | 26 (68.4%) | |
Positive | 70 (44.6%) | 394 (47.8%) | 45 (30.2%) | 12 (31.6%) | |
Seminal vesicle invasion | 0.88 | ||||
Negative | 146 (93.0%) | 742 (90.0%) | 143 (96.0%) | 32 (84.2%) | |
Positive | 11 (7.0%) | 82 (10.0%) | 6 (4.0%) | 105 (9.0%) | |
Pathological Gleason score | 0.01 | ||||
3–6 | 35 (22.3%) | 201 (24.4%) | 62 (41.6%) | 12 (31.6%) | |
7 | 86 (54.8%) | 419 (50.8%) | 57 (38.3%) | 17 (44.7%) | |
8–10 | 36 (22.9%) | 204 (24.8%) | 30 (20.1%) | 9 (23.7%) | |
Pathological stage | 0.01 | ||||
T2 | 85 (54.1%) | 434 (52.7%) | 103 (69.1%) | 25 (65.8%) | |
T3 | 72 (45.9%) | 379 (46.0%) | 46 (30.9%) | 12 (31.6%) | |
T4 | 0 (0.0%) | 11 (1.3%) | 0 (0.0%) | 1 (2.6%) | |
Positive surgical margin | 60 (38.2%) | 351 (42.6%) | 51 (34.2%) | 10 (26.3%) | 0.12 |
PSA recurrence (1 year) | 16 (10.2%) | 127 (15.4%) | 14 (9.4%) | 4 (10.5%) | 0.65 |